Medwell Capital Announces $2 Million Investment in Mimetogen Pharmaceuticals

Mimetogen Pharmaceuticals Enrolls 100th Patient in Phase II Clinical Trial for Dry Eye

MONTREAL and EDMONTON, Feb. 25 /CNW/ - Medwell Capital Corp. (TSXV: MWC) today announced that it has committed to invest up to $2,000,000 in Mimetogen Pharmaceuticals Inc. ("Mimetogen"), a privately-held, clinical-stage company developing a treatment for dry eye disease. Medwell Capital participated in a Series B equity financing with existing Mimetogen investors, iNovia Capital, MSBi Valorisation and VIMAC Milestone Medica.

"The Series B financing gives the company not only longer term financial resources, but also direct access to financial services and business development expertise of Medwell Capital," said Garth Cumberlidge, President and CEO of Mimetogen. "We are very pleased with the progress of the Phase II trial evaluating MIM-D3 for the treatment of the signs and symptoms of dry eye. The company has enrolled over 100 patients and completed dosing of more than 50 patients with final results expected in the second half of 2011."

"Mimetogen fits into our strategy of investing in promising technologies that have significant near term development milestones and large market opportunities," said Kevin Giese, President and CEO of Medwell. "The Phase II results coming out this year are designed to assess the potential for this drug to meet critical unmet needs of a patient group with limited treatment options and blockbuster sales potential."

As part of the financing, Nitin Kaushal, Executive Vice President of Medwell will join the Mimetogen Board of Directors. Medwell Capital will also assist Mimetogen and the current investors with advisory services in potential partnering and financing efforts.

Phase II Clinical Trial of MIM-D3 for Dry Eye Disease
Mimetogen's lead drug candidate for the treatment of dry eye disease, MIM-D3, is a small molecule mimetic of nerve growth factor (NGF). NGF is a naturally occurring protein in the eyes that is responsible for the maintenance of corneal nerves and epithelium, mucin and tear production. In contrast to most other products in development or on the market, MIM-D3 is designed to quickly and directly improve the quality of the tears produced by the eyes whilst reducing symptoms of chronic burning and stinging. Dry eye disease is estimated to be a $1 billion US market for which there is currently only one FDA-approved treatment.

Mimetogen is currently enrolling patients in a Phase II randomized, double-masked, multi-center, placebo-controlled trial designed to evaluate the safety, tolerability and efficacy of MIM-D3 in improving the signs and symptoms of dry eye.

Mimetogen has contracted Ora Inc., as the Clinical Research Organization (CRO) for the trial. The trial is being conducted using Ora's CAE™ System. Ora is the world's leading independent ophthalmic product development firm, with 32 FDA approvals during its 30-year history. For further information please visit

About Dry Eye Disease

Dry eye disease is one of the most common ophthalmic problems, with an estimated 30 million people in North-America suffering from it and a worldwide prevalence closely paralleling that of the United States.  Dry eye is a chronic multifactorial disease of the tears, the ocular surface and the adjacent neurological tissue that results in symptoms of discomfort, visual disturbance and tear film instability that may lead to permanent damage and scars to the ocular surface.

About Mimetogen Pharmaceuticals
Mimetogen Pharmaceuticals, Inc. began operations in 2006, developing the use of peptidomimetics as novel approaches to treat diseases with high unmet medical needs. The underlying technology has been developed at McGill University and the Lady Davis Institute for Medical Research in Montréal. The Company is currently developing novel therapeutic approaches for ophthalmic indications including dry eye disease, glaucoma and other degenerative diseases of the retina.  Mimetogen also possesses a pipeline of lead compounds for non-ophthalmic indications (such as neurodegenerative disease and pain).  Please visit the corporate website at

About Medwell Capital Corp.
Medwell Capital Corp. is a Canadian-based service provider of capital and advisory services for the healthcare industry.  For further information please visit

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events.  These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements.  Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Corporation's ongoing quarterly and annual reporting.  We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Medwell Capital Corp.

For further information:

Tony Hesby  
Ryan Giese Garth Cumberlidge
Medwell Capital Corporation                     Mimetogen Pharmaceuticals Inc.
780-413-7152 617-395-8580
780-408-3040 Fax 617-507-8537 Fax
E-mail: E-mail:
Internet: Internet:
Ross Marshall  
Investor Relations  
416-815-0700 ext. 238  
416-815-0080 Fax  

Organization Profile

Medwell Capital Corp.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890